Company intelligence / Profile preview
GenFleet Therapeutics
Shanghai, Shanghai, Chinagenfleet.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
GenFleet's lead product Dupert® (fulzerasib) is the first approved KRAS G12C inhibitor in China and the third globally. It received NDA priority review designation and two breakthrough therapy designations. The first-line combination therapy of fulzerasib and cetuximab has progressed into phase II study in Europe, marking the world's first integration of KRAS and EGFR inhibitors for first-line non-small cell lung cancer treatment[1][2].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesbiologicsantibodies
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
InnoventVerastem OncologySELLASMerckBeiGene
Beyond the preview
Go deeper on GenFleet Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenFleet Therapeutics.